NYSE:IQV (USA) Also trade in: Germany UK

IQVIA Holdings Inc

$ 158.67 0 (0%)
Volume: 2,729,170 Avg Vol (1m): 1,336,169
Market Cap $: 31.30 Bil Enterprise Value $: 41.84 Bil
P/E (TTM): 131.13 P/B: 4.84
Earnings Power Value 118.08
Net Current Asset Value -61.95
Tangible Book -54.8
Projected FCF 57.5
Median P/S Value 82.01
Graham Number 0
Peter Lynch Value 15.67
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 5/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 0.09
Cash-To-Debt ranked lower than
93.10% of 261 companies
in the Diagnostics & Research industry.
Industry Max: 32990, Med: 3.52, Min: 0.01
IQV: 0.09
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.08, Med: 0.29, Max: 0.51
Current: 0.09
0.08
0.51
Equity-to-Asset 0.29
Equity-to-Asset ranked lower than
82.01% of 239 companies
in the Diagnostics & Research industry.
Industry Max: 0.97, Med: 0.61, Min: -2.81
IQV: 0.29
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: -0.55, Med: -0.11, Max: 0.41
Current: 0.29
-0.55
0.41
Debt-to-Equity 1.71
Debt-to-Equity ranked lower than
85.98% of 164 companies
in the Diagnostics & Research industry.
Industry Max: 22.86, Med: 0.36, Min: 0.01
IQV: 1.71
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: -7.77, Med: -2.56, Max: 1.71
Current: 1.71
-7.77
1.71
Debt-to-EBITDA 5.84
Debt-to-EBITDA ranked lower than
88.79% of 116 companies
in the Diagnostics & Research industry.
Industry Max: 77.72, Med: 1.77, Min: 0.03
IQV: 5.84
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: 3.16, Med: 4.98, Max: 8.48
Current: 5.84
3.16
8.48
Interest Coverage 1.92
Interest Coverage ranked lower than
93.25% of 163 companies
in the Diagnostics & Research industry.
Industry Max: 15605.52, Med: 76.01, Min: 0.54
IQV: 1.92
Ranked among companies with meaningful Interest Coverage only.
Interest Coverage range over the past 10 years
Min: 1.95, Med: 3.48, Max: 6.71
Current: 1.92
1.95
6.71
Piotroski F-Score 4
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 1.80
DISTRESS
GREY
SAFE
Beneish M-Score -2.71
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 3.65%
WACC 9.08%

Profitability & Growth : 6/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % 7.80
Operating Margin ranked higher than
62.40% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 53.36, Med: -0.59, Min: -70300
IQV: 7.8
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: 7.77, Med: 9.34, Max: 11.82
Current: 7.8
7.77
11.82
Net Margin % 2.35
Net Margin ranked higher than
86.72% of 241 companies
in the Diagnostics & Research industry.
Industry Max: 41.13, Med: -2.48, Min: -119600
IQV: 2.35
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: 1.06, Med: 4.44, Max: 13.16
Current: 2.35
1.06
13.16
ROE % 3.43
ROE ranked higher than
86.36% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 61.7, Med: -6.75, Min: -12038.19
IQV: 3.43
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: 1.78, Med: 3.52, Max: 15.36
Current: 3.43
1.78
15.36
ROA % 1.09
ROA ranked higher than
77.10% of 262 companies
in the Diagnostics & Research industry.
Industry Max: 1174.65, Med: -4.54, Min: -1248.4
IQV: 1.09
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: 0.57, Med: 7.75, Max: 20.82
Current: 1.09
0.57
20.82
ROC (Joel Greenblatt) % 182.67
ROC (Joel Greenblatt) ranked higher than
96.53% of 259 companies
in the Diagnostics & Research industry.
Industry Max: 17601.65, Med: -9.57, Min: -3842027.78
IQV: 182.67
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: 151.3, Med: 219.28, Max: 338.36
Current: 182.67
151.3
338.36
3-Year Total Revenue Growth Rate 22.00
3-Year Revenue Growth Rate ranked lower than
60.44% of 182 companies
in the Diagnostics & Research industry.
Industry Max: 371, Med: 4.8, Min: -100
IQV: 3.1
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: 1.5, Med: 5.3, Max: 9
Current: 3.1
1.5
9
3-Year Total EBITDA Growth Rate 34.80
3-Year EBITDA Growth Rate ranked higher than
54.49% of 178 companies
in the Diagnostics & Research industry.
Industry Max: 141.7, Med: 10.1, Min: -340.1
IQV: 13.9
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: 5.8, Med: 12.15, Max: 22.2
Current: 13.9
5.8
22.2
3-Year EPS w/o NRI Growth Rate -26.20
3-Year EPS w/o NRI Growth Rate ranked higher than
76.07% of 163 companies
in the Diagnostics & Research industry.
Industry Max: 138.7, Med: 10.1, Min: -301
IQV: -26.2
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
N/A

» IQV's 30-Y Financials

Financials (Next Earnings Date: 2019-07-24)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NYSE:IQV

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Medical Diagnostics & Research » Diagnostics & Research    NAICS : 621399    SIC : 8099
Compare NYSE:A XSWX:LONN NAS:IDXX NYSE:MTD XAMS:PHIA SHSE:603259 NYSE:LH NYSE:WAT NYSE:DGX NAS:EXAS XTER:SRT3 TSE:6869 NAS:DXCM NYSE:PKI NAS:ILMN XPAR:BIM NYSE:BIO NYSE:QGEN XPAR:ERF NAS:ICLR
Traded in other countries QTS.Germany 0JDM.UK
Address 83 Wooster Heights Road, Danbury, CT, USA, 06810
IQVIA was created from the merger of the healthcare data and analytics of IMS Health with the global contract research organization powerhouse of Quintiles. The CRO segment focuses primarily on providing outsourced phase 2-4 clinical trials for pharmaceutical, device, and diagnostic companies. The legacy IMS business provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers.

Ratios

Current vs industry vs history
PE Ratio (TTM) 131.13
PE Ratio ranked higher than
80.53% of 113 companies
in the Diagnostics & Research industry.
Industry Max: 1345, Med: 35, Min: 0.33
IQV: 131.13
Ranked among companies with meaningful PE Ratio only.
PE Ratio range over the past 10 years
Min: 15.67, Med: 24.43, Max: 291.95
Current: 131.13
15.67
291.95
Forward PE Ratio 25.06
Forward P/E ranked higher than
77.50% of 40 companies
in the Diagnostics & Research industry.
Industry Max: 78.74, Med: 9999, Min: 11.64
IQV: 25.06
Ranked among companies with meaningful Forward P/E only.
N/A
PE Ratio without NRI 131.13
PE without NRI ranked higher than
80.53% of 113 companies
in the Diagnostics & Research industry.
Industry Max: 1345, Med: 35.56, Min: 0.34
IQV: 131.13
Ranked among companies with meaningful PE without NRI only.
PE without NRI range over the past 10 years
Min: 15.67, Med: 24.43, Max: 291.95
Current: 131.13
15.67
291.95
Price-to-Owner-Earnings 40.29
Price-to-Owner-Earnings ranked higher than
88.16% of 76 companies
in the Diagnostics & Research industry.
Industry Max: 1523.53, Med: 36.75, Min: 4.91
IQV: 40.29
Ranked among companies with meaningful Price-to-Owner-Earnings only.
Price-to-Owner-Earnings range over the past 10 years
Min: 14.92, Med: 27.75, Max: 40.29
Current: 40.29
14.92
40.29
PB Ratio 4.84
PB Ratio ranked higher than
70.61% of 245 companies
in the Diagnostics & Research industry.
Industry Max: 270, Med: 4.02, Min: 0.15
IQV: 4.84
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 2.02, Med: 2.82, Max: 4.84
Current: 4.84
2.02
4.84
PS Ratio 3.10
PS Ratio ranked higher than
67.39% of 230 companies
in the Diagnostics & Research industry.
Industry Max: 6350, Med: 3.81, Min: 0.07
IQV: 3.1
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 1.07, Med: 1.6, Max: 3.1
Current: 3.1
1.07
3.1
Price-to-Free-Cash-Flow 48.73
Price-to-Free-Cash-Flow ranked lower than
62.50% of 80 companies
in the Diagnostics & Research industry.
Industry Max: 1356.19, Med: 29.22, Min: 0.35
IQV: 48.73
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
Price-to-Free-Cash-Flow range over the past 10 years
Min: 14.11, Med: 23.67, Max: 48.73
Current: 48.73
14.11
48.73
Price-to-Operating-Cash-Flow 27.60
Price-to-Operating-Cash-Flow ranked lower than
58.76% of 97 companies
in the Diagnostics & Research industry.
Industry Max: 1739.7, Med: 19.94, Min: 0.35
IQV: 27.6
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 12.19, Med: 18.13, Max: 27.6
Current: 27.6
12.19
27.6
EV-to-EBIT 53.64
EV-to-EBIT ranked lower than
80.51% of 118 companies
in the Diagnostics & Research industry.
Industry Max: 341.21, Med: 25.06, Min: 5.74
IQV: 53.64
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: 13.7, Med: 17.8, Max: 56.6
Current: 53.64
13.7
56.6
EV-to-EBITDA 21.64
EV-to-EBITDA ranked higher than
57.58% of 132 companies
in the Diagnostics & Research industry.
Industry Max: 486.47, Med: 20.75, Min: 3.94
IQV: 21.64
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: 11.5, Med: 14.4, Max: 29.3
Current: 21.64
11.5
29.3
EV-to-Revenue 3.97
EV-to-Revenue ranked higher than
61.57% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 19679, Med: 4.24, Min: 0.09
IQV: 3.97
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 1.3, Med: 1.9, Max: 4
Current: 3.97
1.3
4
PEG Ratio 9.64
PEG Ratio ranked higher than
77.08% of 48 companies
in the Diagnostics & Research industry.
Industry Max: 128.13, Med: 3.26, Min: 0.32
IQV: 9.64
Ranked among companies with meaningful PEG Ratio only.
PEG Ratio range over the past 10 years
Min: 1.19, Med: 5.77, Max: 19.89
Current: 9.64
1.19
19.89
Current Ratio 1.14
Current Ratio ranked lower than
85.60% of 250 companies
in the Diagnostics & Research industry.
Industry Max: 97.84, Med: 2.58, Min: 0.02
IQV: 1.14
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 1.09, Med: 1.29, Max: 1.65
Current: 1.14
1.09
1.65
Quick Ratio 1.14
Quick Ratio ranked lower than
75.20% of 250 companies
in the Diagnostics & Research industry.
Industry Max: 97.84, Med: 2.14, Min: 0.02
IQV: 1.14
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 1.09, Med: 1.29, Max: 1.65
Current: 1.14
1.09
1.65
Days Sales Outstanding 41.20
Days Sales Outstanding ranked higher than
71.57% of 204 companies
in the Diagnostics & Research industry.
Industry Max: 521.64, Med: 67.51, Min: 1
IQV: 41.2
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 25, Med: 32.37, Max: 52.7
Current: 41.2
25
52.7
Days Payable 113.20
Days Payable ranked lower than
91.98% of 187 companies
in the Diagnostics & Research industry.
Industry Max: 981.81, Med: 63.34, Min: 1
IQV: 113.2
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 8.02, Med: 11.45, Max: 23.64
Current: 113.2
8.02
23.64

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -18.30
3-Year Share Buyback Rate ranked lower than
67.22% of 180 companies
in the Diagnostics & Research industry.
Industry Max: 3.4, Med: -7.9, Min: -1732.6
IQV: -18.3
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -22, Med: -9.4, Max: 2.5
Current: -18.3
-22
2.5

Valuation & Return

Current vs industry vs history
Price-to-Projected-FCF 2.76
Price-to-Intrinsic-Value-Projected-FCF ranked higher than
56.00% of 75 companies
in the Diagnostics & Research industry.
Industry Max: 449, Med: 2.41, Min: 0.47
IQV: 2.76
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
N/A
Price-to-Median-PS-Value 1.93
Price-to-Median-PS-Value ranked lower than
77.72% of 193 companies
in the Diagnostics & Research industry.
Industry Max: 7.22, Med: 1.01, Min: 0.01
IQV: 1.93
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.68, Med: 1, Max: 1.75
Current: 1.93
0.68
1.75
Price-to-Peter-Lynch-Fair-Value 10.13
Price-to-Peter-Lynch-Fair-Value ranked higher than
76.67% of 30 companies
in the Diagnostics & Research industry.
Industry Max: 15.31, Med: 2.01, Min: 0.83
IQV: 10.13
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
Price-to-Peter-Lynch-Fair-Value range over the past 10 years
Min: 1.21, Med: 3.81, Max: 17.49
Current: 10.13
1.21
17.49
Earnings Yield (Joel Greenblatt) % 1.86
Earnings Yield (Greenblatt) ranked higher than
64.15% of 265 companies
in the Diagnostics & Research industry.
Industry Max: 17.42, Med: -0.98, Min: -1428.57
IQV: 1.86
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: 1.8, Med: 5.6, Max: 7.3
Current: 1.86
1.8
7.3
Forward Rate of Return (Yacktman) % 14.95
Forward Rate of Return ranked higher than
71.43% of 70 companies
in the Diagnostics & Research industry.
Industry Max: 7802.99, Med: 8.45, Min: -35.9
IQV: 14.95
Ranked among companies with meaningful Forward Rate of Return only.
Forward Rate of Return range over the past 10 years
Min: 15, Med: 16.2, Max: 22.3
Current: 14.95
15
22.3

More Statistics

Revenue (TTM) (Mil) $ 10,533
EPS (TTM) $ 1.21
Beta 1.12
Volatility % 27.84
52-Week Range $ 97.65 - 159.55
Shares Outstanding (Mil) 197.5

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 4
Positive ROA Y
Positive CFROA Y
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy N
Less Shares Outstanding yoy Y
Higher Gross Margin yoy N
Higher Asset Turnover yoy N